 BioCardia BCDA, a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the independent Data Safety Monitoring Board DSMB has completed its prespecified data review for the Phase III pivotal CardiAMPTM Heart Failure Trial, based on a review of all available safety data for all patients randomized in the trial. The DSMB indicated there were no safety concerns with the CardiAMP study results and recommended that the trial continue, as planned. The ongoing multi-center, double-blinded, randomized 3:2, controlled pivotal CardiAMP Heart Failure Trial is expected to enroll 260 patients at up to 40 centers nationwide. 